PhD Defence Johannes Tobias Reckweg

Keywords: Psychedelics, 5-MeO-DMT, Depression, clinical studies
 

"The Light at the End of the Tunnel: Safety and Efficacy of 5-MeO-DMT in Treatment-Resistant Depression"

The research described in this thesis focused on the psychedelic and psychoactive effects of the psychedelic drug Mebufotenin (5-MeO-DMT), as well as its safety and therapeutic efficacy. A prominent feature of 5-MeO-DMT is its ability to elicit a psychedelic state, which has been linked to feelings of profoundness and meaningfulness. This state, sometimes referred to as a mystical or peak experience, has been linked to therapeutic effects in patients with anxiety or depression. Two clinical studies were conducted, in which a vaporized 5-MeO-DMT formulation was first delivered to healthy volunteers and, in the second study, to patients with treatment-resistant depression (TRD), in order to assess safety and efficacy. Results indicated that higher doses, eliciting stronger and more profound effects, were related to better clinical efficacy in reducing depressive symptoms, while still being well tolerated and safe.  

Click here for the full dissertation.

Click here for the live stream.